Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Clinical stage drug development company Evgen Pharma reported narrower losses as costs fell.
For the six months ended 30 September 2021, pre-tax losses narrowed to £1.5 million from £1.8 million year-on-year. The company didn't generate a revenue for the half year.
In the last six months, 'we have developed trial designs for the phase I PK/PD study, and in collaboration with senior GBM clinicians, the design of the GBM proof of principle study,' the company said.
'In parallel we have progressed a new and commercially viable formulation of SFX-01 that will deployed in these trials.'